Easing Acute Allergic Discomfort

This medication is commonly used to provide supportive relief for the most distressing subjective symptoms of eye allergies. It is applied in addressing sensations like eye itching, burning, and irritation, providing symptomatic relief and contributing to improved day-to-day comfort. Combinations of antihistamine and vasoconstrictor drops are typically utilized for the management of symptoms associated with mild acute presentations.

---

Summary of Symptom Relief

Alergoftal is used to address the visible signs of irritation associated with allergens, including visible redness of the eye and excessive tearing (watery eyes).

---

Use for Episodic Flare-ups

It is commonly used to provide supportive relief during acute and episodic flare-ups of allergic eye symptoms, such as those triggered by pollen, dander, or dust. This support is relevant in conditions where symptoms may intensify temporarily, including allergic conjunctivitis and hay fever-related eye discomfort. This assistance is intended for periods of heightened discomfort and to assist with managing symptoms that may interfere with daily functioning.

“This medication may be relevant in contexts where additional symptomatic support is needed, and is used to help with symptoms that interfere with daily comfort.”

Regulatory References

1. NIH MedlinePlus overview on Allergic Conjunctivitis

Alergoftal, which combines the antihistamine Antazoline and the vasoconstrictor Naphazoline, is generally indicated for adults experiencing symptoms associated with allergic conjunctivitis, such as redness, tearing, itching, and burning. It is intended for short-term symptomatic relief.

However, Alergoftal is not suitable for everyone. Certain conditions and patient groups are considered contraindications due to the potential risks, primarily related to the vasoconstrictive effects of Naphazoline.

---

Who Should NOT Use Alergoftal

Patient Group or Condition	Reason for Contraindication
Narrow-angle glaucoma	The vasoconstrictor component can increase intraocular pressure.
Underlying eye disease	May complicate or worsen pre-existing ocular conditions.
Hypersensitivity	Known allergy to Antazoline, Naphazoline, or any other ingredient (e.g., benzalkonium chloride).
Systemic Conditions	Patients with high blood pressure, hyperthyroidism (overactive thyroid), or certain heart diseases should exercise caution due to the risk of systemic absorption of Naphazoline.
Children	This formulation is typically not recommended for use in children.

Individuals with diabetes or thyroid disease should also consult a healthcare provider before use. Additionally, those who wear contact lenses must remove them before application and wait at least 10–15 minutes before reinserting them.

Alergoftal eye drops contain naphazoline (a decongestant) and antazoline (an antihistamine). While ophthalmic preparations have limited systemic absorption, potential interactions exist, primarily due to the vasoconstrictive effects of naphazoline.

Major Interactions to Avoid

The most critical interactions involve medications that affect blood pressure and heart rate. Due to the risk of dangerously high blood pressure (hypertensive crisis), Alergoftal should not be used if you have taken or are currently taking certain types of drugs, including:

• Monoamine Oxidase Inhibitors (MAOIs): These are antidepressants or anti-Parkinson drugs, such as isocarboxazid, phenelzine, selegiline, or tranylcypromine. The risk is present for up to 14 days after stopping the MAOI.
• Ergot Alkaloids: Medications used for migraines, such as ergotamine or methylergonovine, can increase the risk of severe hypertension and vasoconstriction.

Moderate Interactions and Precautions

Caution is advised when using Alergoftal with other medications that can increase blood pressure or heart rate, or have similar anticholinergic effects as antazoline, which may lead to cumulative side effects like blurred vision or dry mouth. These may include:

• Tricyclic Antidepressants (TCAs): Such as amitriptyline or imipramine.
• Other Sympathomimetics: Medications with similar decongestant effects (oral or nasal) or stimulants.
• Beta-Blockers (Ophthalmic and Systemic): Used to lower blood pressure or eye pressure, as naphazoline may potentially decrease their effectiveness.

Always inform your healthcare provider of all prescription and non-prescription medicines, vitamins, and herbal supplements you are using to ensure the combination is safe.

Alergoftal is a fixed-dose combination containing two active pharmacological agents: antazoline and naphazoline.

Antazoline acts as a competitive antagonist at the Histamine H1-receptor (H1). Antazoline binds to the H1 receptor, preventing endogenous histamine from activating this Gq-coupled receptor. H1 receptor blockade modulates the histamine-mediated intracellular signaling cascade, which involves the activation of phospholipase C and subsequent increase in inositol trisphosphate (IP3) and intracellular calcium (Ca^2+) concentration. This action occurs at the level of conjunctival epithelial cells and other responsive cellular targets, counteracting histamine-driven cellular processes.

Naphazoline is an agonist at alpha-adrenergic receptors (alpha1 and alpha2 subtypes), primarily targeting receptors located on vascular smooth muscle cells in the conjunctiva. Activation of alpha1-receptors, which are typically Gq-coupled, initiates a downstream cascade involving elevated intracellular Ca^2+, leading to vasoconstriction of the small conjunctival arterioles and venules. This localized vasoconstrictive effect modulates regional ocular hemodynamics and reduces vascular permeability at the system level.

Alergoftal is an ophthalmic solution that must be administered via the topical ophthalmic route only. The administration of this medicine is structured as an intermittent, short-term treatment intended for as-needed applications.

Standardized Dosing and Frequency

The standardized dose for adults and children 12 years and over is the instillation of one or two drops into the affected eye(s) per application. The medicine is applied up to two or three times daily, establishing a typical interval of approximately six to eight hours between each dose.

Administration Rules and Duration Limits

Guidelines for use limit continuous application to a maximum of 5 days of continuous use. Furthermore, it is specified that use must be discontinued if symptoms are not relieved or if the condition worsens after 48 to 72 hours.

Special Procedural Conditions

Soft contact lenses must be removed prior to instillation, and a minimum waiting period of 15 minutes is required before they can be re-inserted. If another ophthalmic product must be used, an interval of at least 5 minutes is required between the application of the two medicines. As an integrity rule, the solution must not be used if it becomes cloudy or changes color, and the dispenser tip must not touch any surface to prevent contamination. Use in children under 12 years is not generally recommended in standardized labeling.

Recent Clinical Evidence

Clinical research has investigated the use of this agent, which combines an antihistamine (antazoline phosphate) and a vasoconstrictor (naphazoline hydrochloride), in studies of acute allergic conjunctivitis. The dual composition is designed to address both the allergic symptoms and the associated redness.

Key Study Findings

Studies focused on the effect of the combination drop in reducing the core signs and symptoms of allergic conjunctivitis, primarily ocular itching and conjunctival redness.

Research comparing the combination drop to individual components or other treatments has been conducted. One study comparing a combination of naphazoline and antazoline (or pheniramine) to other treatments noted that while all products offered some degree of symptom improvement, the combination product resulted in comparable therapeutic benefit for itching, tearing, and redness.

Comparative Observations

Treatment Comparison	Outcome Focus	Reported Finding
Naphazoline/Antazoline vs. Levocabastine	Onset of Action	Combination product reported a more rapid onset (around 30 minutes).
Naphazoline/Antazoline vs. Other Antihistamines	Ocular Discomfort	The combination product induced a higher level of discomfort compared to newer topical treatments in one study.

Safety Profile

Due to the presence of a vasoconstrictor, studies highlight the importance of short-term use for this specific combination. Potential adverse effects noted in trials and clinical experience typically include local reactions such as pupil dilation (mydriasis), stinging, or persistent redness. Clinicians note that prolonged use of vasoconstrictor agents carries a potential risk of rebound redness (conjunctivitis medicamentosa) when discontinued.

Common questions about Alergoftal (FAQ)

Q: What is Alergoftal used for?

A: Alergoftal is officially indicated for the treatment of allergic conjunctivitis of various origins, including seasonal and perennial (non-seasonal) allergies. Regulatory documents state that it is intended to relieve symptoms such as redness, itching, and watering of the eyes associated with these allergic reactions. This medicine is specifically for ophthalmic (eye) use.

Q: How long does it take for Alergoftal to start working?

A: According to the official product information, Alergoftal usually begins to provide relief from symptoms of allergic conjunctivitis shortly after application. Its effect is generally rapid in onset. The rapid onset of action is intended to provide prompt symptom relief, although the overall duration of the effect can vary among individuals.

Q: Can I use Alergoftal if I wear soft contact lenses?

A: Regulatory documents indicate that soft contact lenses should be removed before applying Alergoftal. Official documentation advises that soft contact lenses should be removed before administration. Patients should follow the instructions in the product label regarding the precise waiting period before reinsertion. This is a common precaution related to the product’s ingredients.

Q: Is Alergoftal available over the counter, or do I need a prescription?

A: The official product information specifies the supply status of Alergoftal. This status dictates whether it is available only with a prescription (Rx) or can be obtained without one (Over-the-Counter or OTC). The specific regulatory status (prescription-only or over-the-counter) is determined by local authorities and may vary by country.

Q: Does Alergoftal contain any preservatives?

A: Yes, according to the official product information, Alergoftal contains a specific preservative to maintain the sterility and stability of the eye drop solution. The exact type of preservative, such as benzalkonium chloride, is listed in the regulatory documents. Information regarding the preservative is included in the official labeling for patients who monitor ingredient sensitivities.

Q: What should I do if I miss a dose of Alergoftal?

A: Regulatory documents state that if a dose is missed, it should generally not be compensated for by applying a double dose. The official label provides instructions on when to apply the next dose, which is typically at the regularly scheduled time. Following the labeled dosing frequency is noted as important for optimizing the intended therapeutic effect.

Q: Can children use Alergoftal?

A: Official product information specifies the minimum age for which Alergoftal is indicated and considered safe for use. Official product information specifies the minimum age for which the medicine is approved, such as 4 years or older. Use in children, including the minimum age and specific dosage instructions, is outlined strictly within the official regulatory documentation.

Official Storage and Disposal Requirements

The storage and disposal of Alergoftal (Antazoline and Naphazoline Hydrochloride ophthalmic solution) are strictly defined by regulatory guidelines to maintain sterility and stability.

Requirement Type	Official Labeled Condition
Temperature & Protection	Store below 25 C (room temperature); protect from light and freezing (do not freeze).
Container & Integrity	Keep the container tightly closed. Do not let the dropper tip touch any surface to prevent contamination.
Stability (In-Use)	The unused contents must be discarded 4 weeks (1 month) after opening the bottle. Do not use if the solution changes color or is cloudy.
Child Safety	Keep the medication out of the reach of children and pets.
Disposal	Dispose of unused or expired product according to local regulatory guidelines, typically via drug take-back programs.

These conditions ensure the product's integrity: controlled temperature and protection from light prevent degradation, while the 4-week discard rule maintains sterility after first use.